Evidence map›Paper›PMID 25332886›Full record

ArticleSpringerPlus2014

Zoledronic acid prevents decreases in bone mineral density in patients with prostate cancer undergoing combined androgen blockade.

Satoshi Nishizawa, Takeshi Inagaki, Akinori Iba, Kazuro Kikkawa, Yoshiki Kodama, Nagahide Matsumura, Yasuo Kohjimoto, Isao Hara

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in SpringerPlus, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Satoshi NishizawaDepartment of Urology, Wakayama Medical University School of Medicine, 811-1 Kimiidera, Wakayama, 641-8509 Japan ; Department of Urology, Rinku General Medical Center, Osaka, Japan.
Takeshi InagakiDepartment of Urology, Kinan Hospital, Wakayama, Japan.
Akinori IbaDepartment of Urology, Wakayama Medical University School of Medicine, 811-1 Kimiidera, Wakayama, 641-8509 Japan.
Kazuro KikkawaDepartment of Urology, Wakayama Medical University School of Medicine, 811-1 Kimiidera, Wakayama, 641-8509 Japan.
Yoshiki KodamaDepartment of Urology, Wakayama Medical University School of Medicine, 811-1 Kimiidera, Wakayama, 641-8509 Japan.
Nagahide MatsumuraDepartment of Urology, Wakayama Medical University School of Medicine, 811-1 Kimiidera, Wakayama, 641-8509 Japan.
Yasuo KohjimotoDepartment of Urology, Wakayama Medical University School of Medicine, 811-1 Kimiidera, Wakayama, 641-8509 Japan.
Isao HaraDepartment of Urology, Wakayama Medical University School of Medicine, 811-1 Kimiidera, Wakayama, 641-8509 Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to evaluate the effect of zoledronic acid (ZA) on bone mineral density (BMD) in patients with prostate cancer receiving combined androgen blockade (CAB) as a first-line androgen deprivation therapy. Patients receiving CAB for prostate cancer without bone metastasis were candidates for this study. Forty-two patients were randomly assigned to receive either ZA or no treatment. BMD were measured at baseline and at 12 months. Bone-turnover markers, including cross-linked N-telopeptide of type I collagen (NTX), C-telopeptide of type I collagen (ICTP), and bone-specific alkaline phosphatase (BAP), were assessed during study periods. Patients on ZA maintained BMD after a year of treatment. Change in T-score from baseline differed significantly between the two groups (P=0.009). An inverse correlation was demonstrated between baseline and change in T-score in the ZA group. While ZA prevented an increase in ICTP and BAP, the increase in NTX was suppressed only in patients with low baseline T-score. ZA prevented a decrease in BMD in patients undergoing CAB, especially those with lower baseline BMD.

Indexed as

Androgen deprivation therapyBone mineral densityCombined androgen blockadeProstate cancerZoledronic acid

Identifiers

PMID25332886
PMCPMC4197198

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.